Another study has shown that estrogen treatment restores serum FGF21 concentrations and reduces NAFLD in female rats probably via activation of hepatic estrogen receptor α [23]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.